Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

BACKGROUND: Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization be...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroidl, Inge, Winter, Simon, Rubio-Acero, Raquel, Bakuli, Abhishek, Geldmacher, Christof, Eser, Tabea M., Déak, Flora, Horn, Sacha, Zielke, Anna, Ahmed, Mohamed I. M., Diepers, Paulina, Guggenbühl, Jessica, Frese, Jonathan, Bruger, Jan, Puchinger, Kerstin, Reich, Jakob, Falk, Philine, Markgraf, Alisa, Fensterseifer, Heike, Paunovic, Ivana, Thomschke, Angelika, Pritsch, Michael, Riess, Friedrich, Saathoff, Elmar, Hoelscher, Michael, Olbrich, Laura, Castelletti, Noemi, Wieser, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474769/
https://www.ncbi.nlm.nih.gov/pubmed/37658454
http://dx.doi.org/10.1186/s12985-023-02167-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474769/
https://www.ncbi.nlm.nih.gov/pubmed/37658454
http://dx.doi.org/10.1186/s12985-023-02167-z

Ejemplares similares